Efficacy of hepatic resection vs transarterial chemoembolization for solitary huge hepatocellular carcinoma

Table 2 Clinicopathologic features of propensity score-matched study participants with solitary huge hepatocellular carcinoma (≥ 10 cm) receiving hepatic resection or transarterial chemoembolization n (%)

Variables	HR (n = 61)	TACE (n = 61)	Standardized difference, %	P-value
Age (yr)	46.3 ± 11.9	48.1 ± 12.4	4.3	0.808
Gender (M/F), n (%)	58 (95.1)/3 (4.9)	58 (95.1)/3 (4.9)	0	1.000
Tumor size (cm)	11.9 ± 3.0	11.8 ± 2.3	2.3	0.915
HBsAg (+)	60 (98.4)	60 (98.4)	0	1.000
Child-Pugh class
A	58	58	0	1.000
B	3	3
Cirrhosis	52 (85.2)	51 (83.6)	4.4	0.803
AFP (ng/mL)
≥ 400	31 (50.8)	32 (52.5)	3.3	0.856
≤ 400	30 (49.2)	29 (47.5)
Total bilirubin (μmol/L)	13.6 ± 6.8	15.1 ± 8.1	8.9	0.261
ALT (U/L)	59.0 ± 56.5	60.2 ± 42.6	3.0	0.888
AST (U/L)	57.6 ± 30.3	57.4 ± 36.3	0.4	0.983
Prothrombin time (s)	12.7 ± 1.4	13.0 ± 2.3	9.7	0.504
Albumin (g/L)	37.7 ± 4.6	37.7 ± 6.6	0.5	0.972
Platelet count (109/L)	218.1 ± 86.9	213.0 ± 88.6	3.8	0.750
Vascular invasion	5 (8.2)	6 (9.8)	5.5	0.752

Values with ‘‘±’’ are written as mean ± SD. ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; AFP: Alpha-fetoprotein; HR: Hepatic resection; TACE: Transarterial chemoembolization.